CR
Crinetics
CRNX · NASDAQ
$84.95 -0.01% (-$0.01)
1M +1.03%
Market Cap $9.00B
P/E Ratio -
Div. Yield -
ROE 44.22%
Bulios Fair Price
$50.74
40.3% downside
Current Price
$84.95
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CRNX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
3 /100
Expensive P/S 213.54x
P/B 7.55x
P/E N/A
Growth
98 /100
Growing Rev. growth 17.56%
Book val. growth 46.38%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 99.16%
Net margin 1,189.88%
Op. margin 1,302.52%
Quality
0 /100
Poor ROIC 43.99%
ROE 44.22%
ROA 37.95%
Debt
100 /100
Low Debt/Equity 0.04x
Current ratio 15.57x
Int. coverage N/A
Stability
29 /100
Unstable Beta 0.13x
Rev. volatility 396.81%
EPS volatility 17.07%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CRNX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
R. Scott Struthers
Employees
594
Headquarters
San Diego
Upcoming events
05 NOV
Earnings
Upcoming earnings report